SOURCE-LINKED STUDY SUMMARY
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Abstract summarizedQuality not appraised
- What was studied
- Randomized, open-label phase 3 substudy comparing weekly tirzepatide with daily titrated insulin degludec for liver fat and abdominal adipose tissue.
- Who / model studied
- The MRI population included 296 insulin-naive adults with type 2 diabetes, BMI at least 25, and fatty liver index at least 60; outcomes were assessed at 52 weeks.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Mean liver fat began at 15·71%. At week 52, pooled tirzepatide 10 mg and 15 mg reduced it by -8·09% versus -3·38% with degludec; the estimated between-group difference was -4·71%. Visceral and subcutaneous abdominal fat volumes also fell more with tirzepatide.
- Limitations & context
- Open-label MRI substudy rather than the full trial population; 296 of 502 assessed people entered the MRI analysis. Eli Lilly funded the study. The abstract states no author-framed limitation.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s2213-8587(22)00070-5